Quick Answer
ZyVersa Therapeutics, Inc. reported Cash and Equivalents of $928.4 thousand for fiscal year 2021.
ZyVersa Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $928.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $213.6K | — | -37.2% |
| June 30, 2022 | $340.0K | — | -59.0% |
| March 31, 2022 | $830.2K | — | -10.6% |
| December 31, 2021 | $928.4K | — | — |
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on April 15, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: